久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

Stem Cell Sciences 
Company profile
We are one of the first, if not the first, organisation with the R&D know-how, to develop a range of derived stem cells for use on a commercial and industrial scale.
Founded in 1994, we pioneered many of the unique technologies required to grow, differentiate, and purify embryonic and neural stem cells. Today we hold an extensive portfolio of patents and patent applications in both adult and embryonic stem cell fields. For example we were first with our neural stem cell technology to enable the derivation and growth of SCS’s patented NS cells – the first, mammalian tissue stem cells of any kind that can be stably grown outside the body as pure stem cells.

Our technologies permit the generation of highly purified stem cells and their differentiated progeny for use in genetic, pharmacological and toxicological screens. Moreover, these technologies can be utilised to provide pure populations of appropriate cell types for transplantation therapies. international biotechnology and pharmaceutical companies including Pfizer, Sanofi-Aventis, GSK, Chemicon, Deltagen and Lexicon have benefited from our commercial and industrial approach.

SCS takes pride in its long-standing relationships with leading academic centres of excellence in the stem cell field, which help maintain our position at the cutting edge of the stem cell industry.

This legacy is your assurance of quality, consistency in high volume, and a guaranteed supply of stem cells for use in research and drug discovery. As stem cell-based therapies and regenerative medicine move from the laboratory to the clinic, only SCS is equipped with a highly automated environment to meet the upsurge in demand.

We are headquartered in Cambridge, UK in a new, fully equipped cell culture facility featuring state of the art automation for cell culture, in the form of the CompacT SelecT? from  The Automation Partnership as well as cell analysis equipment. Our NS cells are the first adherent brain stem cells to be grown on CompacT SelecT?. We also have a business development office in California (USA) and a research operation in Australia. We listed on AIM of the London Stock Exchange (LSE) in 2005 and on the Australian Securities Exchange (ASX) in 2007.

SCS research centre of excellence in Australia
Since 1994 SCS has operated in Australia from our research centre of excellence, advancing embryonic stem cell (ES) biology (rat, human and mouse) at our laboratory within the Monash University campus, Melbourne. Here our team of some of world’s leading experts in stem cell biology are engaged in developing rat ES cells, new human ES lines (under license from human supernumerary IVF embryos), early neural lineage specification and looking for refined ways of simplifying these cells’ establishment, growth and differentiation.